PD-L1-positive NSCLC (KEYNOTE-024): A multicentre, international, rand omised, open-label phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1600-1609.
[8] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1 positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. [9] Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus...
KEYNOTE-02411 was a phase 3 trial in which 305 patients who had untreated, advanced NSCLC with high PD-L1 expression were randomized to receive either pembrolizumab (anti-PD-1 therapy) or the investigator's choice of platinum doublet chemotherapy. Patients with sensitizing EGFR mutations or trans...
KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). JR Brahmer,ES Kim,J Zhang,... - 《Journal of Clinical ...
Clinical trial identification NCT02142738. Editorial acknowledgement Medical writing assistance was provided by Rozena Varghese, PharmD, CMPP, of ICON plc (North Wales, PA, USA). This assistance was funded by the study sponsor, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., ...
[3]Kanikarla Marie P,Haymaker C,Parra ER,et al.Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.Clin Cancer Res.2021 Apr 2:clincanres.0163.2021.doi:10.1158/1078-0432.CCR-21-0163.Epub ahead of print. ...
This trial is registered with ClinicalTrials.gov (NCT03189719). Results Patients Of 749 patients enrolled globally in KEYNOTE-590 [1], 141 were enrolled in Japan (pembrolizumab–chemotherapy, 74 [52.5%]; placebo–chemotherapy, 67 [47.5%]). Baseline characteristics were generally balanced between ...
I am Mark Socinski, executive medical director of the Florida Hospital Cancer Institute in Orlando, Florida. Participating today on our distinguished panel are Maximilian Hochmair, MD, of the Respiratory Oncology Unit at Otto Wagner Hospital in Vienna, Austria; Leora Horn, MD, MSc, FRCPC, Ingr...
The trial is registered with Clinicaltrials.gov: NCT02142738.doi:10.1111/cas.14647Miyako SatouchiKaname NosakiToshiaki TakahashiKazuhiko NakagawaKatsuyuki HottaJohn Wiley & Sons, LtdCancer Science
[15] Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previ-ously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819-30. ...